Fig. 3. Coinactivation of PRC2 genes and trx acts synergistically to increase the proportion of Imp⁺ tNBs and amplify tumor growth.

(A) Control poxⁿ>pros^RNAi tumors or poxⁿ>pros^RNAi tumors with RNAi-mediated inactivation of E(z) or trx or coinactivation of trx and E(z). Immunostainings against Mira (green) label all tNBs. Immunostainings against Chinmo (red) label the subpopulation of Imp⁺ tNBs. The dashed lines delimit the area of the tumor in the VNC of 1-day-old adults. Images are single confocal sections. Scale bars, 50 μm. (B) Box plots recapitulating quantifications of tumor volumes (in cubic micrometers) for the genotypes indicated in (A). Tumor volume measurements are made on the basis of anti-Mira immunostaining. T in uppercase indicates RNAi lines from the TRiP provided by the Bloomington Stock Center, while V in uppercase indicates RNAi lines from the VDRC. (C) Immunostainings of tumors showing apoptotic cells with anti-Dcp1 antibody. Apoptosis is strongly reduced upon coinactivation of E(z) and trx compared to the single inactivation of E(z) or trx. Scale bars, 50 μm. Images are single confocal sections. (D) Box plots recapitulating quantifications of proportions of Imp⁺ tNBs for the genotypes indicated in (A). Imp⁺ tNBs are identified with an anti-Chinmo antibody. All measurements are made in tumors that persist in the VNCs of 1-day-old adults